GlobalDatas pharmaceuticals report, Doxorubicin (Gastric Cancer) - Analysis and Forecast to 2020 provides Doxorubicin estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Doxorubicin including historical sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Doxorubicin including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2002-2020 for Doxorubicin in each of the US, EU5 and Japan markets

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

List of Tables

Table 1: Gastric Cancer Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer , Global Market Size Forecasts ($bn), 2009-2020 7
Table 3: Approval History of Doxorubicin 15
Table 4: Drug Risk Benefit Score 16
Table 5: Gastric Cancer, The US, EU-5 and Japan, Sales Forecast for Doxorubicin ($m), 20022020 20
Table 6: Gastric Cancer, The US, Sales Forecast for Doxorubicin ($m), 20022020 22
Table 7: Gastric Cancer, The UK, Sales Forecast for Doxorubicin ($m), 20022020 23
Table 8: Gastric Cancer, France, Sales Forecast for Doxorubicin ($m), 20022020 24
Table 9: Gastric Cancer, Germany, Sales Forecast for Doxorubicin ($m), 20022020 25
Table 10: Gastric Cancer, Italy, Sales Forecast for Doxorubicin ($m), 20022020 26
Table 11: Gastric Cancer, Spain, Sales Forecast for Doxorubicin ($m), 20022020 27
Table 12: Gastric Cancer, Japan, Sales Forecast for Doxorubicin ($m), 20022020 28

List of Figures

Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption , The US, 1976-2006 6
Figure 4: Gastric Cancer , Global Market Size Forecasts ($bn), 2009-2020 7
Figure 5: Oncology, Global, Estimated Incidence 2008-2030 8
Figure 6: Gastric Cancer, Global, Estimated Incidence 2008-2030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classifications 11
Figure 10: Classification of Gastric Cancer (US and EU) 12
Figure 11: Classification of Gastric Cancer (Japan) 12
Figure 12: Drug Model Diagram of Doxorubicin for the US and the EU 18
Figure 13: Drug Model Diagram of Doxorubicin for Japan 18
Figure 14: Drug Dosage Diagram of Doxorubicin for the US and the EU 19
Figure 15: Gastric Cancer, The US, EU-5 and Japan, Sales Forecast for Doxorubicin ($m), 20022020 20
Figure 16: Distribution of Doxorubicin sales in the US, EU-5 and Japan (2010) 21
Figure 17: Gastric Cancer, The US, Sales Forecast for Doxorubicin ($m), 20022020 22
Figure 18: Gastric Cancer, The UK, Sales Forecast for Doxorubicin ($m), 20022020 23
Figure 19: Gastric Cancer, France, Sales Forecast for Doxorubicin ($m), 20022020 24
Figure 20: Gastric Cancer, Germany, Sales Forecast for Doxorubicin ($m), 20022020 25
Figure 21: Gastric Cancer, Italy, Sales Forecast for Doxorubicin ($m), 20022020 26
Figure 22: Gastric Cancer, Spain, Sales Forecast for Doxorubicin ($m), 20022020 27
Figure 23: Gastric Cancer, Japan, Sales Forecast for Doxorubicin ($m), 20022020 28